Roche Drops Emugrobart in Obesity After Interim Futility; Chugai Takes It Back
- Roche ended obesity development of emugrobart (GYM329), an anti-latent-myostatin sweeping antibody meant to preserve muscle alongside GLP-1 therapy, after a Phase 2 GYMINDA interim analysis made meaningful weight loss unlikely.
- Rights revert to Chugai, which is preparing to resume development in spinal muscular atrophy and is open to out-licensing; the antibody had already missed in SMA and FSHD trials in March.
💡 Points
This dents the muscle-preservation thesis in obesity: the pitch was that myostatin blockade adds lean-mass benefit on top of incretins, and this antibody didn't deliver. Other myostatin and activin-pathway programs will face sharper partner questions about what retained lean mass means clinically. A rights return usually signals a deprioritized asset, and a Phase 3 in SMA after an earlier SMA miss looks like a long shot.
Roche drops muscle-sparing obesity antibody after flunked interim analysis ↗